Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex

Key Inclusion Criteria: * The subject is capable of understanding and complying with protocol requirements. * The subject or the subject's legally acceptable representative signs and dates a written, informed consent/assent form and any required privacy authorization prior to the initiation of any study procedures. * Subject has a documented genetic mutation consistent with EBS. * Subject has completed study CCP-020-301 or participated in study CCP-020-101. * Subject/caregiver agrees to report use of any topical therapies applied to EBS lesions * If the subject is a woman of childbearing potential, she has a negative urine pregnancy test and agrees to use an approved effective method of birth control, for the duration of the study. * Subject is non-lactating and is not planning for pregnancy during the study period. * Subject is willing and able to follow all study instructions and to attend all study visits. Key Exclusion Criteria: * Subject has EBS lesions to be treated that are infected * Subject has evidence of a systemic infection or has used systemic antibiotics within 7 days prior to Baseline Visit. * The subject was discontinued from the feeder study due to an adverse event judged to be related or possibly related to the study medication. * Subject has experienced a change in clinical status from the feeder study that puts the subject at undue risk to participate.